AnaptysBio Plans to Continue Enroll Patients in the Midstage Study with an Enrollment Target of 10 Patients

AnaptysBio Inc. released their topline results Monday and the new data from the study showed highly compelling efficacy. Wedbush’s David Nierengarten reiterated an Outperfrom rating on AnaptysBio with $146 price target.

For more on David Nierengarten’s comments: Wedbush: Investors Largely Underappreciating AnaptysBio